Myrthe J. van Dijk

One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study

Myrthe J. van Dijk, Minke A.E. Rab, Brigitte A. van Oirschot et al. · Blood Advances · 2023 · 29 citations · Full text

Medicine, Hematology, Pharmacology +12

Modelling of hydrological processes

Myrthe J. van Dijk, R.H. Boekelman, T.H.M. Rientjes · University of Twente Research Information · 1999 · 13 citations

Natural Resources, Earth Sciences, Hydrology +12

Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease

Myrthe J. van Dijk, Titine Ruiter, Sigrid van der Veen et al. · HemaSphere · 2024 · 12 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

A novel missense variant in <scp><i>ATP11C</i></scp> is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia

Myrthe J. van Dijk, Brigitte A. van Oirschot, Alexander N. Harrison et al. · American Journal of Hematology · 2023 · 10 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +15